Status:
TERMINATED
Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Conditions:
Leukemia, Myeloid, Acute
Minimal Residual Disease
Eligibility:
All Genders
18+ years
Brief Summary
Purpose: The purpose of this trial is to investigate whether a digital array assay can detect trace amounts of residual leukemia and predict relapse in acute myeloid leukemia (AML) patients in remissi...
Detailed Description
Minimal residual disease (MRD) refers to the presence of cancer cells that are present after therapy and not otherwise detectable by clinical findings, including standard clinical assays and radiograp...
Eligibility Criteria
Inclusion
- Adult patients (≥18 years of age) diagnosed with AML who are going to undergo stem cell transplant (SCT). These subjects must provide written informed consent to participate.
- Subjects must have an identified mutation that has been validated on the multiplex daPCR assay.
Exclusion
- Adult patients (≥18 years of age) diagnosed with AML who are scheduled to undergo SCT at the NCCH who do not provide written informed consent to participate are ineligible.
Key Trial Info
Start Date :
May 28 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 25 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04920188
Start Date
May 28 2021
End Date
May 25 2024
Last Update
July 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
North Carolina Cancer Hospital (NCCH)
Chapel Hill, North Carolina, United States, 27514